Congratulations to Adaptive Phage Therapeutics for a New Award: “Development of Personalized Bacteriophage Therapeutic for the Treatment of Bacterial Infections”
Published on May 28, 2025
Multidrug antibiotic resistance is a growing crisis. Supported by MTEC, Adaptive Phage Therapeutics will evaluate the human safety and efficacy of a novel bacteriophage prototype for the treatment of bacterial infections. The goal is to evaluate its safety and efficacy in humans and gain FDA approval for precision infection treatment.
Award Highlight
Multidrug antibiotic resistance is an emerging medical challenge that is reaching crisis proportions. Existing antimicrobials are losing their efficacy, and the drug development pipeline for traditional small molecule antimicrobials (antibiotics) is limited in new alternative candidates. One alternative is bacteriophage therapy. Bacteriophages (phages) are viruses that specifically attack bacteria. This MTEC-funded project will evaluate the human safety and efficacy of a novel bacteriophage prototype for the treatment of bacterial infections. This program aims to support the activities required for the clinical development and ultimate approval by the U.S. Food and Drug Administration of a precision bacteriophage therapeutic.